Although a defined clinical phenotype is used to distinguish Alzheimer's disease (AD) from other late-life dementias, the accuracy of antemortem tests for the diagnosis of AD are imperfect. Ultimately, AD is defined most securely when the clinical phenotype is coupled with the postmortem detection of specific brain lesions considered to be """"""""pathological signatures"""""""" of AD. Uncertainty about the antemortem diagnosis of AD is likely to impede efforts to develop and test potentially useful therapies. Indeed, as many as 20% of elderly patients with a dementia ascribed to AD will fail to exhibit postmortem evidence of the neurofibrillary tangles (NFTs) and senile plaques (SPs) identified as hallmarks of AD. This subset of elderly patients with an AD-like dementia, but no AD pathology, may exhibit lesions characteristic of Pick's disease, diffuse Lewy body (LB) disease (DLBD) or other neurodegenerative diseases associated with profound cognitive dysfunction. The consistent assignment of elderly demented patients followed by the Clinical Core (Core B) of this ADCC to 1 of several diagnostic categories (e.g. AD, DLBD) is central to the mission of this ADCC. Hence, the goal of the Neuropathology Core (Core C) of this ADCC is to obtain and thoroughly characterize postmortem tissues from all deceased ADCC patients for whom permission for an autopsy is obtained. Complete autopsies will be performed and objective criteria will be used to sort the cases into well defined diagnostic categories. Further, all of the vital information on this case material (e.g. age of the patient, diagnosis, postmortem interval, means of tissue denaturation, tissue recipients, etc.) will be recorded in an electronic data base for correlation with clinical data obtained on these patients in Core B. Finally, Core C will serve as a resource to other investigators in this ADCC, a related Program Project (""""""""Molecular Substrates Of Aging & Neuron Death"""""""", P01 AG-09215) on AD and idiopathic Parkinson's disease (PD), and new research projects on AD stimulated by the presence of this ADCC at the University of Pennsylvania.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG010124-09
Application #
6098327
Study Section
Project Start
1999-07-01
Project End
2000-06-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
9
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Wang, Qi; Guo, Lei; Thompson, Paul M et al. (2018) The Added Value of Diffusion-Weighted MRI-Derived Structural Connectome in Evaluating Mild Cognitive Impairment: A Multi-Cohort Validation1. J Alzheimers Dis 64:149-169
Kirson, Noam Y; Scott Andrews, J; Desai, Urvi et al. (2018) Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer's Disease. J Alzheimers Dis 61:295-307
Barnes, Josephine; Bartlett, Jonathan W; Wolk, David A et al. (2018) Disease Course Varies According to Age and Symptom Length in Alzheimer's Disease. J Alzheimers Dis 64:631-642
Zee, Jarcy; Xie, Sharon X (2018) The Kaplan-Meier Method for Estimating and Comparing Proportions in a Randomized Controlled Trial with Dropouts. Biostat Epidemiol 2:23-33
Kovacs, Gabor G; Kwong, Linda K; Grossman, Murray et al. (2018) Tauopathy with hippocampal 4-repeat tau immunoreactive spherical inclusions: a report of three cases. Brain Pathol 28:274-283
Stites, Shana D; Milne, Richard; Karlawish, Jason (2018) Advances in Alzheimer's imaging are changing the experience of Alzheimer's disease. Alzheimers Dement (Amst) 10:285-300
Wang, Tingyan; Qiu, Robin G; Yu, Ming (2018) Predictive Modeling of the Progression of Alzheimer's Disease with Recurrent Neural Networks. Sci Rep 8:9161
Stites, Shana D; Harkins, Kristin; Rubright, Jonathan D et al. (2018) Relationships Between Cognitive Complaints and Quality of Life in Older Adults With Mild Cognitive Impairment, Mild Alzheimer Disease Dementia, and Normal Cognition. Alzheimer Dis Assoc Disord 32:276-283
Hansson, Oskar; Seibyl, John; Stomrud, Erik et al. (2018) CSF biomarkers of Alzheimer's disease concord with amyloid-? PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement 14:1470-1481
Agogo, George O; Ramsey, Christine M; Gnjidic, Danijela et al. (2018) Longitudinal associations between different dementia diagnoses and medication use jointly accounting for dropout. Int Psychogeriatr 30:1477-1487

Showing the most recent 10 out of 720 publications